Branched chain keto acids are excreted in urine in:
So, when there's a deficiency in branched-chain alpha-keto acid dehydrogenase, which is the case in maple syrup urine disease (MSUD), the keto acids aren't properly metabolized. This leads to their accumulation and excretion in urine. MSUD is an autosomal recessive disorder. The other options might include other metabolic disorders like phenylketonuria (PKU) or maple syrup urine disease itself. Wait, but the question is about keto acids, so the correct answer would be MSUD. Other options might be other inborn errors of metabolism that don't involve branched-chain amino acids. For example, PKU is about phenylalanine. So the answer should be maple syrup urine disease. Let me verify the options again. If the options were A. Maple syrup urine disease, B. PKU, C. Alkaptonuria, D. Galactosemia, then A is correct. The explanation would focus on the enzyme deficiency leading to excretion of these keto acids.
**Core Concept**
This question assesses understanding of **inborn errors of metabolism**, specifically disorders affecting **branched-chain amino acid (BCAA) metabolism**. Branched-chain keto acid dehydrogenase (BCKDH) deficiency in **maple syrup urine disease (MSUD)** impairs BCAA catabolism, leading to accumulation of their corresponding keto acids.
**Why the Correct Answer is Right**
In **maple syrup urine disease (MSUD)**, mutations in the **BCKDH complex** prevent conversion of branched-chain alpha-keto acids (e.g., alpha-ketoisocaproate from leucine) to acyl-CoA derivatives. These toxic keto acids are excreted in urine, giving it a characteristic sweet odor. The disorder causes neurological damage due to BCAA and keto acid toxicity, requiring dietary restriction and metabolic monitoring.
**Why Each Wrong Option is Incorrect**
**Option A:** *Phenylketonuria (PKU)* involves phenylalanine hydroxylase deficiency, not branched-chain amino acids.
**Option B:** *Alkaptonuria* is due to homogentisate oxidase deficiency, leading to homogentisic acid excretion.
**Option C:** *Galactosemia* results from galactose-1-phosphate uridyltransferase deficiency, not BCAA metabolism.
**Clinical Pearl / High-Yield Fact**
Remember **"MSUD = maple syrup urine + branched-chain ketoaciduria"**. Newborn screening detects MSUD via elevated BCAA levels. Early diagnosis is critical to prevent encephalopathy and death. Distinguish from PKU, which presents with fair skin and intellectual disability, not sweet-smelling urine.
**Correct Answer: A. Maple syrup urine disease**